Country Guide: Filing a Patent in Bangladesh

Bangladesh is the eighth most populous country on earth, with over 170 million people, and the world's second-largest garment exporter. Its economy has grown at approximately 6–7% annually for over a decade, driven by ready-made garments (RMG), pharmaceuticals, agriculture, and a rapidly expanding digital services sector. As Bangladesh graduates from Least Developed Country (LDC) status — a transition scheduled for November 2026 — its IP obligations under the WTO's TRIPS Agreement are changing in ways that directly affect inventors and patent holders worldwide.

Understanding Bangladesh's IP system today means understanding a country in active legal transition: the Bangladesh Patents Act 2023 has replaced the colonial-era Patents and Designs Act 1911, and the IP framework is being modernised in preparation for full TRIPS compliance after LDC graduation.

The Hard Truth About Bangladesh and TRIPS

Bangladesh has been a member of the WTO since 1995 and has actively used the TRIPS flexibilities available to Least Developed Countries. The most significant of these is the LDC pharmaceutical patent waiver: LDC members are not obligated to grant or enforce patents on pharmaceutical products, or to protect test data submitted for pharmaceutical marketing approvals. This waiver has allowed Bangladesh's generic pharmaceutical industry — one of the most productive in Asia — to manufacture and export medicines, including HIV/AIDS antiretrovirals, tuberculosis drugs, and cancer treatments, without paying royalties to originator patent holders.

The current pharmaceutical waiver extends to January 2033 (or until Bangladesh ceases to be an LDC, whichever comes first). Bangladesh's LDC graduation is currently scheduled for November 24, 2026, though there has been discussion of potential delay to 2032. A WTO-agreed three-year "smooth transition" period (2026–2029) provides some diplomatic cushion.

What this means for patent holders:

If you hold pharmaceutical patents and Bangladesh is manufacturing generic versions of your patented drugs: this is currently legal under WTO rules while Bangladesh retains LDC status. After graduation, Bangladesh must begin providing full TRIPS-compliant pharmaceutical patent protection. The post-graduation transition period will be a critical window for patent filing strategies in Bangladesh's pharmaceutical sector.

For non-pharmaceutical inventions: The LDC waiver specifically covers pharmaceuticals. For other technology areas — garment manufacturing machinery, agricultural technology, construction equipment, digital services, consumer goods — Bangladesh's patent system applies standard TRIPS obligations.

Bangladesh's Patent System

DPDT: Department of Patents, Designs and Trademarks

The Department of Patents, Designs and Trademarks (DPDT) under the Ministry of Industries administers patents, industrial designs, trademarks, and geographic indications in Bangladesh. DPDT is headquartered in Dhaka. The administrative head is the Director General, who holds powers akin to a civil court under the new legislation.

The Bangladesh Patents Act 2023

Bangladesh enacted the Bangladesh Patents Act 2023 to replace the colonial-era Patents and Designs Act 1911. The 2023 Act came into force on February 27, 2025, representing the most significant modernisation of Bangladesh's patent system since independence. Key features of the new law:

• Patent term: 20 years from filing date — aligning with the TRIPS standard (replacing the old 16-year term under the 1911 Act)
• Mandatory examination request within 36 months of filing — applications where examination is not requested within this period are deemed abandoned
• Pre-grant opposition: Any person may oppose a pending application within 6 months of publication
• Post-grant opposition: Available after grant, providing a mechanism for validity challenges
• Publication at 18 months from filing/priority date
• Renewal fees starting from the 6th year after filing

Language: DPDT conducts proceedings in English and Bengali. Applications can be filed in English, making Bangladesh one of the most accessible patent systems for English-language applicants.

Types of Protection

Patent:

• Term: 20 years from filing date (under the 2023 Act)
• Examination: Substantive examination after mandatory examination request
• Coverage: Products, processes, and improvements
• Note: DPDT's examination capacity is still developing — timelines of 4–6 years from filing to grant are estimated

No utility model system. Bangladesh does not offer utility models or petty patents.

Filing Routes

Direct national filing at DPDT: File through DPDT's filing system (increasingly digital under the e-IPO portal). Foreign applicants must appoint a registered Bangladeshi patent agent.

Paris Convention priority filing: Bangladesh is a member of the Paris Convention. File directly at DPDT within 12 months of a priority application in another country, claiming priority.

PCT status: REQUIRES VERIFICATION BEFORE RELYING ON THIS ROUTE. There are conflicting sources regarding Bangladesh's PCT membership. Some sources indicate Bangladesh joined the PCT, while a 2025 Bangladeshi legal source states that Bangladesh is not a PCT member and that foreign entities must file a direct national application using the Paris Convention. Inventors planning to designate Bangladesh in a PCT application should verify current PCT membership status with WIPO or a qualified Bangladeshi patent agent before filing. If Bangladesh is not a PCT member, the only route for claiming priority is direct filing under the Paris Convention within 12 months.

Bangladesh's LDC Status and Patent Strategy

The Pharmaceutical Window

The most strategically significant aspect of Bangladesh's patent system is what it does not currently protect: pharmaceutical patents, until LDC graduation. For originator pharmaceutical companies, this has historically meant accepting that Bangladesh's generic manufacturers could produce and export medicines. For generic pharmaceutical companies — particularly those in Bangladesh itself — the LDC window has provided access to technology without licensing obligations.

The post-graduation transition: After Bangladesh graduates from LDC status (currently planned for November 2026), it will be required to:

• Begin granting and enforcing patents on pharmaceutical products
• Protect undisclosed test data submitted for pharmaceutical marketing approvals
• Comply with the full range of TRIPS obligations

The Bangladesh Patents Act 2023 provides the legal framework for this transition. For originator pharmaceutical companies planning to seek patent protection in Bangladesh after graduation, now is the time to establish priority dates — file directly at DPDT under the Paris Convention to secure your position before the transition period creates complexity. For generic manufacturers currently operating in Bangladesh, the transition will require careful legal analysis of which products will be affected and when.

Technology Transfer and LDC Flexibilities

Bangladesh retains other TRIPS flexibilities available to LDCs beyond the pharmaceutical waiver:

• Technology transfer provisions: Article 66.2 of TRIPS requires developed country members to provide incentives to enterprises for technology transfer to LDCs
• Compulsory licensing: Bangladesh can issue compulsory licences under domestic law for reasons of public interest, national emergency, and non-commercial government use, consistent with TRIPS Article 31
• Transition periods for other IP: Various TRIPS implementation obligations have extended transition periods for LDCs across IP categories

Priority Sectors for Bangladesh IP

Ready-Made Garments (RMG)

Bangladesh's RMG sector is the country's largest industry, employing over 4 million workers and generating over 80% of export earnings. Patent activity in this sector covers textile machinery and processing equipment, dye and finishing chemical processes, automated cutting and sewing technologies, and sustainable textile production methods (growing importance as EU sustainability regulations affect Bangladeshi exports to European markets).

Pharmaceuticals

Bangladesh's pharmaceutical sector is one of the most sophisticated in Asia. Companies including Square Pharmaceuticals, Beximco Pharmaceuticals, and Incepta Pharmaceuticals export to over 100 countries. Post-LDC graduation, this sector will need to engage more formally with the global patent system — both as a target of originator pharmaceutical company patent assertions and as a filer of its own innovation patents.

Agriculture and Food Technology

Bangladesh faces serious climate resilience challenges — flooding, salinity intrusion, and heat stress — that have driven substantial agricultural R&D. International and Bangladeshi research institutions hold patents on flood-tolerant, salt-tolerant, and high-yield rice varieties.

Digital Services

Bangladesh's growing IT sector provides digital services to global clients. The 2023 Act provides a more modern framework for software-related patent questions than the 1911 Act, though DPDT's examination practice for software patents is still developing.

Enforcement in Bangladesh

The Court System

Patent enforcement in Bangladesh proceeds through the civil court system. The 2023 Act strengthens enforcement mechanisms compared to the 1911 Act, with the Director General of DPDT holding civil court-equivalent powers for certain matters.

Practical enforcement challenges remain:

• Court timelines in Bangladesh are long — commercial cases can take 5–10+ years
• Technical patent expertise in the Bangladeshi judiciary is limited but improving
• Cost of sustained commercial litigation relative to the size of most Bangladeshi IP disputes can make formal enforcement economically challenging

Alternative approaches:

For foreign patent holders dealing with infringement in Bangladesh, pragmatic approaches include: negotiated licensing arrangements (particularly for major Bangladeshi companies with export markets in countries where the patent holder has stronger protection), customs border enforcement, and engaging through industry associations and government ministries for technology sectors where regulation is involved.

Cost Summary

Bangladesh remains among the most affordable patent jurisdictions globally by total cost — reflecting both low government fees and competitive local agent rates.

Sources

1. DPDT — Department of Patents, Designs and Trademarks (Bangladesh) — Official national IP authority; filing procedures and fee schedules
2. Bangladesh Patents Act 2023 — Current statutory framework replacing the 1911 Act
3. WIPO — Bangladesh Country Profile — Treaty memberships, PCT status, and IP office information
4. WTO TRIPS Council — LDC Pharmaceutical Waiver — TRIPS flexibilities for Least Developed Countries including pharmaceutical patent waivers

Information current as of April 2026. Patent fees, timelines, and office procedures change — verify with the national patent office before filing.